Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

An analysis of dosage volume for halfway doses in the Victoza Pen.

Kroon L.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1625-6. No abstract available.

2.

Accuracy of dosage volume for halfway doses in the Victoza Pen.

King AB, Wolfe GS.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1623-4. No abstract available.

3.

[Basal insulin and liraglutide combined in a pen].

Rausch R.

Med Monatsschr Pharm. 2015 Apr;38(4):154-6. German. No abstract available.

PMID:
26364391
4.

Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.

Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A.

J Clin Pharmacol. 2011 Jun;51(6):951-5. doi: 10.1177/0091270010374474. Epub 2010 Jul 29. No abstract available.

PMID:
20671294
5.

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ.

Obesity (Silver Spring). 2011 Jul;19(7):1342-9. doi: 10.1038/oby.2011.50. Epub 2011 Mar 17.

6.

Attempted suicide with liraglutide overdose did not induce hypoglycemia.

Nakanishi R, Hirose T, Tamura Y, Fujitani Y, Watada H.

Diabetes Res Clin Pract. 2013 Jan;99(1):e3-4. doi: 10.1016/j.diabres.2012.10.017. Epub 2012 Nov 11.

PMID:
23149376
7.

Liraglutide-induced acute pancreatitis.

Jeyaraj S, Shetty AS, Kumar CR, Nanditha A, Krishnamoorthy S, Raghavan A, Raghavan K, Ramachandran A.

J Assoc Physicians India. 2014 Jan;62(1):64-6.

PMID:
25327099
8.

Hormone copycats.

Gebel E.

Diabetes Forecast. 2012 Jun;65(6):36, 38-9. No abstract available.

PMID:
22737769
9.

An accidental liraglutide overdose: case report.

Elmehdawi RR, Elbarsha AM.

Libyan J Med. 2014 Jan 20;9:23055. doi: 10.3402/ljm.v9.23055. eCollection 2014. No abstract available.

10.

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A.

Diabetes Obes Metab. 2013 Jul;15(7):642-9. doi: 10.1111/dom.12076. Epub 2013 Feb 25.

11.

Liraglutide (Victoza) for type 2 diabetes.

[No authors listed]

Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7.

PMID:
20360660
12.

Liraglutide in clinical practice: dosing, safety and efficacy.

Peterson GE, Pollom RD.

Int J Clin Pract Suppl. 2010 Oct;(167):35-43. Review.

PMID:
20949699
13.

Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.

Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, Gong CX.

J Alzheimers Dis. 2013;37(3):637-48. doi: 10.3233/JAD-130491.

PMID:
23948890
14.
15.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group.

N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.

16.

The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.

Thayer S, Wei W, Buysman E, Brekke L, Crown W, Grabner M, Raparla S, Quimbo R, Cziraky MJ, Hu W, Cuddihy R.

Adv Ther. 2013 Dec;30(12):1128-40. doi: 10.1007/s12325-013-0074-8. Epub 2013 Nov 30.

17.

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.

Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S.

Diabet Med. 2008 Sep;25(9):1129-31. doi: 10.1111/j.1464-5491.2008.02484.x. No abstract available.

18.

Liraglutide: from clinical trials to clinical practice.

Gough SC.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:33-40. doi: 10.1111/j.1463-1326.2012.01576.x. Review.

PMID:
22405267
19.

An overview of the pharmacokinetics, efficacy and safety of liraglutide.

Bode B.

Diabetes Res Clin Pract. 2012 Jul;97(1):27-42. doi: 10.1016/j.diabres.2011.12.015. Epub 2012 Jan 14. Review.

PMID:
22245694
20.

Potential of liraglutide in the treatment of patients with type 2 diabetes.

Deacon CF.

Vasc Health Risk Manag. 2009;5(1):199-211. Epub 2009 Apr 8. Review.

Supplemental Content

Support Center